Business Context and Reporting Period
Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: MannKind is a biopharmaceutical company in the development stage, focused on therapeutic products for diabetes and cancer. Its lead investigational product, AFRESA (Technosphere Insulin System), is in Phase 3 clinical trials. The company has no commercial products and has incurred significant losses since inception.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Cumulative (Inception to Sep 30, 2008) |
|---|---|---|---|
| Revenue | $0 | $20 | $2,988 |
| Net Loss | $(68,496) | $(219,744) | $(1,300,783) |
| Net Loss Per Share (Basic/Diluted) | $(0.67) | $(2.17) | $(13.03) |
| Cash and Cash Equivalents | $31,582 (as of Sep 30, 2008) | ||
| Marketable Securities | |||
| Total Current Assets | $102,942 | ||
| Total Liabilities | $168,207 | ||
| Stockholders' Equity | $163,425 | ||
| Senior Convertible Notes | $112,128 (Principal approx. $115M) |
Cash Flow (Nine Months Ended Sep 30, 2008):
- Net cash used in operating activities: $(201,045)
- Net cash used in investing activities: $(135,878)
- Net cash provided by financing activities: $220
Material Changes vs. Prior Period
- Liquidity Decline: Cash and cash equivalents decreased significantly from $368.3 million at December 31, 2007, to $31.6 million at September 30, 2008. This was driven by a net decrease in cash of $336.7 million during the nine-month period.
- Investment Activity: The company purchased $63.7 million in marketable securities during the nine months ended September 30, 2008, compared to net sales of securities in the prior year period.
- Operating Expenses:
- R&D Expenses: Decreased by 14% ($9.2 million) for the three months ended September 30, 2008, compared to the prior year, primarily due to decreased clinical development costs for AFRESA.
- G&A Expenses: Increased by 25% ($2.7 million) for the three months ended September 30, 2008, driven by higher employee-related costs and stock-based compensation.
- Interest Income: Decreased significantly due to lower market interest rates and a lower investment balance.
Guidance, Outlook, and Risks
Outlook and Capital Resources:
Management believes existing capital resources, including a $350 million loan arrangement with its principal stockholder (of which $150 million is intended to be drawn by February 28, 2009), will fund operations through the fourth quarter of 2009. However, the company expects to need additional capital to continue development and commercialization of AFRESA. Due to global financial market turbulence, raising additional capital may be difficult.
Business Updates:
- Announced "AFRESA" as the proposed trade name for its lead product.
- Released preliminary top-line results from a Phase 3 study in Type 1 diabetes showing comparable A1C reductions to insulin aspart, superior fasting blood glucose, and fewer hypoglycemic events.
- Agreed with Pfizer to transition certain Exubera patients to AFRESA.
Risks and Contingencies:
- Regulatory Approval: No assurance that AFRESA will receive FDA approval. The FDA may require additional studies or impose restrictive labeling.
- Manufacturing: The company is scaling up manufacturing in Danbury, CT, but has never produced commercial quantities. FDA pre-approval inspection is required.
- Collaboration: Partnership discussions were suspended in April 2008 to await Phase 3 data; no agreement has been reached.
- Intellectual Property: Risks of patent infringement litigation and the need to defend proprietary rights.
- Supply Chain: Reliance on single suppliers for insulin and inhaler components.
Investor Verification Checklist
- Cash Runway: Verify the timeline for drawing down the $150 million loan from the principal stockholder and the sufficiency of current cash ($31.6M) to fund operations until then.
- Phase 3 Data: Review the full clinical data for AFRESA to confirm the preliminary results regarding safety, efficacy, and pulmonary function.
- Manufacturing Readiness: Assess the status of the Danbury facility qualification and the timeline for FDA pre-approval inspection.
- Capital Markets: Evaluate the feasibility of raising additional equity or debt given current market conditions and the company's history of losses.
- Convertible Notes: Review the terms of the $115 million Senior Convertible Notes due 2013, including conversion rates and potential dilution.
- Supply Agreements: Confirm the stability of supply contracts for insulin (N.V. Organon) and inhaler components (Vaupell, Inc.).